Literature DB >> 26058601

Cardiomyopathy in Duchenne Muscular Dystrophy: Current Value of Clinical, Electrophysiological and Imaging Findings in Children and Teenagers.

S Dittrich1, M Tuerk2, G Haaker3, V Greim1, A Buchholz4, B Burkhardt5, A Fujak6, R Trollmann7, A Schmid8, R Schroeder2.   

Abstract

BACKGROUND: Progressive cardiomyopathy (CMP) is one main cause of death in DMD. This cross-sectional assessment of different cardiac diagnostic procedures focusses on preterm diagnosis of cardiac dysfunction. PATIENTS: 39 male DMD patients aged 6-20 years were included. 6 patients were still ambulatory, 21 patients received corticosteroid therapy.
METHODS: All patients were investigated by ECG, Holter ECG and heart rate variability (HRV), B-type natriuretic peptide (BNP), echocardiography (TTE), tissue Doppler Imaging (TD) and magnetic resonance imaging (MRI) with Late Gadolinium enhancement (LE) and segmental wall motion analysis (WMA).
RESULTS: 56% of the patients showed repolarization abnormalities and 76% altered HRV. Subnormal ventricular function was found in 25% by TTE and in 34% by MRI. TD differed from normal controls only in the apical septum. In MRI 89% of the patients showed different distribution and intensity of LE and WM restriction. The extent of LE was less in patients after steroid treatment (p<0.05). DISCUSSION: MRI with segmental LE- and WM-analysis seems to be superior to TTE and TD in exploring regional distribution and severity of damage of the myocardium. ECG and HRV abnormalities are common in DMD-patients but not tightly predictive for segmental and global left ventricular dysfunction. Targeted treatment of CMP in DMD needs prospective evaluation.
CONCLUSION: A timely cardiac MRI is the most sensitive investigation for the identification of early myocardial changes in DMD which is a prerequisite for early interventions and therapeutic strategies. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26058601     DOI: 10.1055/s-0034-1398689

Source DB:  PubMed          Journal:  Klin Padiatr        ISSN: 0300-8630            Impact factor:   1.349


  13 in total

Review 1.  Utility of late gadolinium enhancement in pediatric cardiac MRI.

Authors:  Maryam Etesami; Robert C Gilkeson; Prabhakar Rajiah
Journal:  Pediatr Radiol       Date:  2015-12-30

Review 2.  Cardiomyopathy in becker muscular dystrophy: Overview.

Authors:  Rady Ho; My-Le Nguyen; Paul Mather
Journal:  World J Cardiol       Date:  2016-06-26

Review 3.  Heart Rate Variability and Cardiopulmonary Dysfunction in Patients with Duchenne Muscular Dystrophy: A Systematic Review.

Authors:  Talita Dias da Silva; Thais Massetti; Tânia Brusque Crocetta; Carlos Bandeira de Mello Monteiro; Alex Carll; Luiz Carlos Marques Vanderlei; Carlie Arbaugh; Fernando Rocha Oliveira; Luiz Carlos de Abreu; Celso Ferreira Filho; John Godleski; Celso Ferreira
Journal:  Pediatr Cardiol       Date:  2018-04-25       Impact factor: 1.655

Review 4.  Heart Disease in Disorders of Muscle, Neuromuscular Transmission, and the Nerves.

Authors:  Josef Finsterer; Claudia Stöllberger
Journal:  Korean Circ J       Date:  2016-03-21       Impact factor: 3.243

5.  Autonomic Modulation in Duchenne Muscular Dystrophy during a Computer Task: A Prospective Control Trial.

Authors:  Mayra Priscila Boscolo Alvarez; Talita Dias da Silva; Francis Meire Favero; Vitor Engrácia Valenti; Rodrigo Daminello Raimundo; Luiz Carlos Marques Vanderlei; David M Garner; Carlos Bandeira de Mello Monteiro
Journal:  PLoS One       Date:  2017-01-24       Impact factor: 3.240

6.  Circulating Biomarkers for Duchenne Muscular Dystrophy.

Authors:  Annemieke Aartsma-Rus; Pietro Spitali
Journal:  J Neuromuscul Dis       Date:  2015-07-22

Review 7.  Management of cardiac involvement in muscular dystrophies: paediatric versus adult forms.

Authors:  Alberto Palladino; Paola D'Ambrosio; Andrea Antonio Papa; Roberta Petillo; Chiara Orsini; Marianna Scutifero; Gerardo Nigro; Luisa Politano
Journal:  Acta Myol       Date:  2016-12

8.  Randomised placebo-controlled trial of combination ACE inhibitor and beta-blocker therapy to prevent cardiomyopathy in children with Duchenne muscular dystrophy? (DMD Heart Protection Study): a protocol study.

Authors:  John P Bourke; Gillian Watson; Francesco Muntoni; Stefan Spinty; Helen Roper; Michela Guglieri; Chris Speed; Elaine McColl; Ashish Chikermane; Sandeep Jayawant; Satish Adwani; Tracey Willis; Jennifer Wilkinson; Andrew Bryant; Thomas Chadwick; Ruth Wood; Kate Bushby
Journal:  BMJ Open       Date:  2018-12-19       Impact factor: 2.692

Review 9.  Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy.

Authors:  Jacqueline N Robinson-Hamm; Charles A Gersbach
Journal:  Hum Genet       Date:  2016-08-20       Impact factor: 4.132

10.  Mechanical thrombectomy in a young stroke patient with Duchenne muscular dystrophy.

Authors:  Charlotte Spicher; Ruth Schneider; Peter Mönnings; Christiane Schneider-Gold; Dennis Kallenberg; Bilal Cevik; Carsten Lukas; Ralf Gold; Christos Krogias
Journal:  Ther Adv Neurol Disord       Date:  2018-03-01       Impact factor: 6.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.